Global Emphysema Drug Market To Witness Huge Growth By 2026|GlaxoSmithKline plc, Grifols, S.A, AstraZeneca, United Therapeutics Corporation, Sunovion Pharmaceuticals Inc and others.

Global Craniomaxillofacial Devices Market

Global emphysema drug market is rising substantially in the forecast period of 2019-2026, this rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients, high smoking prevalence, growing medical spending, increasing global healthcare expenditure and technological advancements in pharmaceuticals research.

In this market research report, a market study and overview is carried out by taking into account market drivers, market restraints, opportunities and challenges for a particular business. Geographical scope of the products is also taken into consideration methodically for the major global areas such as Asia, North America, South America, and Africa. This helps delineate strategies for the product distribution in those areas. Emphysema drug market report estimates the size of the market with respect to the information on key retailer revenues, development of the industry by upstream and downstream, industry progress, key companies, key developments, along with market segments and application. This superior emphysema drug market report is presented with a full devotion and dedication to the clients that extend their reach to success.

Get Sample Copy Of This Report @

Few of the major competitors currently working in the global emphysema drug market are Intrexon, Pulmonx, Halozyme, Inc, Mariposa Health, BTG International Ltd, Icure, Pfizer Inc, Kamada Pharmaceuticals, Olympus Corporation, Spiration, Inc, Lifetech Scientific, CSL, F. Hoffmann-La Roche Ltd, Angion Biomedica corp, Prometic Life Sciences Inc, GlaxoSmithKline plc, Grifols, S.A, AstraZeneca, United Therapeutics Corporation, Sunovion Pharmaceuticals Inc and others.

Key Developments in the Market

  • In June 2018, Pulmonx developed a new device intended to treat breathing difficulty associated with severe emphysema has been approved by the FDA. The device, Pulmonx’s Zephyr Endobronchial Valve (Zephyr Valve) is a less invasive treatment than options currently available to patients
  • In June 2016, Shire and Kamada Pharmaceuticals received approval from the FDA for the expanded label for self-infusion of the Glassia, an alpha-1 Proteinase Inhibitor, developed for the treatment of emphysema due to severe Alpha-1 Antitrypsin (AAT) deficiency that can be self-infused at home after appropriate training

Competitive Analysis: 

Global emphysema drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of emphysema drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry For Customize Report With Discount at :

Segmentation: Global Emphysema Drug Market

By Type

  • Paraceptal
  • Centrilobular
  • Panlobular

By Mechanism of Action Type

  • Bronchodilators
  • Beta-Agonists
  • Anticholinergics
  • Corticosteroids
  • Phosphodiesterase -4 Inhibitors
  • Mucolytics
  • Others

Stages Type

  • Very mild or Stage 1: FEV1 is about 80 percent of normal
  • Moderate or Stage 2: FEV1 is between 50 and 80 percent of normal
  • Severe or Stage 3: FEV1 is between 30 and 50 percent of normal
  • Very severe or Stage 4: FEV1 is lower than in Stage 3, or the same as Stage 3 but with low blood oxygen levels

Surgery Type

  • Lung Volume Reduction Surgery
  • Lung Transplant Surgery

By Drug Type

  • Aclidinium
  • Formoterol
  • Salmeterol
  • Levalbuterol
  • Ipratropium
  • Olodaterol
  • Fluticasone
  • Budesonide
  • Prednisolone
  • Others

By Treatment

  • Oxygen Therapy
  • Protein Therapy
  • Surgery

By Route of Administration

  • Oral
  • Inhaled
  • Intravenous
  • Others

By Device Type

  • Inhalers
  • Pressurized Metered-Dose Inhalers (MDIs)
  • Dry-Powder Inhalers (DPIs)
  • Nebulizers
  • Soft Mist Inhalers

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Surgical centers
  • Others

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Get Full Table Of content @

Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *